PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15179005-8	2004	In PML-RARA-positive APL about 70% of patients are expected to be cured with a combination of ATRA and anthracycline-based chemotherapy.	Anthracyclines	103-116	PML nuclear body scaffold	Homo sapiens	3-6	
15124139-5	2004	The majority of patients with promyelocytic leukemia with the PML/RARalpha fusion gene can be cured with an all-trans-retinoic acid and anthracycline-based treatment program.	Anthracyclines	136-149	PML nuclear body scaffold	Homo sapiens	62-65	
12642121-6	2003	Standard protocols involving ATRA combined with anthracycline-based chemotherapy, lead to cure of approximately 70% patients with PML-RARalpha-associated APL.	Anthracyclines	48-61	PML nuclear body scaffold	Homo sapiens	130-133	
24592821-2	2014	However, in the majority of patients given all-trans retinoic acid (ATRA)/anthracycline-based induction therapy, PML-RARalpha transcript remains even when haematologic complete remission is achieved.	Anthracyclines	74-87	PML nuclear body scaffold	Homo sapiens	113-116	
10556184-0	1999	A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia.	Anthracyclines	30-43	PML nuclear body scaffold	Homo sapiens	142-145